Tigress Financial initiated coverage of Medline (MDLN) with a Buy rating and $55 price target The firm says the company is positioned for share gains in a “fragmented” and growing healthcare supply market. Medline is concerting low-margin third-party volume into higher-margin Medline Brand products, with hospital brand penetration already rising from 20% to 60%, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- How the $7B Medline (MDLN) IPO Proves Fundamentals Are Back in Vogue
- Medline price target raised to $55 from $50 at BTIG
- Top 3 Trending Stocks, According to Analysts – 1/15/2026
- 2 New IPO Stocks Hit the Market – Morgan Stanley Picks the Superior One to Buy
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!